NR4A1 and ductal breast carcinoma in situ: According to the findings of the IBIS-II and NSABP-B-35 studies, anastrozole has a comparable benefit as adjuvant treatment for postmenopausal patients with hormone-receptor-positive DCIS treated with BCS and RT, albeit with a different toxicity profile [54,55].